Skip to main content

AMGEN INC

For the period ended Dec 31, 2025. Filed Feb 13, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 13, 2026

AMGN$465.23+1.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 2. PROPERTIES

Item 2.PROPERTIES

As of December 31, 2025, we owned or leased approximately 160 properties. The locations and primary functions of significant properties are summarized in the following tables:

U.S. Location:ManufacturingAdministrativeR&DSales and marketingWarehouseDistribution center
Thousand Oaks, CA(1)xxxxxx
Juncos, Puerto Ricoxxxx
West Greenwich, RIxxx
Deerfield, ILxxx
Cambridge, MAx
New Albany, OHxxx
San Francisco, CAx
Tampa, FLxx
Louisville, KYxx
Other U.S. cities(2)xxx
ROW Location:ManufacturingAdministrativeR&DSales and marketingWarehouseDistribution center
Canadaxxx
Chinaxx
Denmarkxxx
Germanyxxx
Icelandxx
Indiax
Irelandxxxxx
Netherlandsxxxxx
Singaporexxxx
Other countries(2)xxxx

(1)Corporate headquarters.

(2)Includes smaller properties in other U.S. and ROW locations, primarily for administrative and sales and marketing.

Excluded from the information above are (i) undeveloped land and leased properties that have been abandoned and (ii) certain buildings we still own but that are no longer used in our business. Additionally, in 2025 we broke ground on our second drug substance manufacturing facility in Holly Springs, North Carolina; announced expansions of our manufacturing network in Ohio and the U.S. territory of Puerto Rico; and broke ground on a new, state-of-the-art science and innovation center at our corporate headquarters in Thousand Oaks, California. There are no material encumbrances on our owned properties.

We believe our facilities are suitable for their intended uses and, in conjunction with our third-party contract manufacturing agreements, provide adequate capacity and are sufficient to meet our expected needs. See Item 1A. Risk Factors for a discussion of the factors that could adversely impact our manufacturing operations and the global supply of our products.

See Item 1. Business—Manufacturing, Distribution and Raw Materials.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.